BioNTech, the German biotech that garnered global attention for its partnership with Pfizer on a COVID-19 vaccine, has turned its attention back to one of its earlier mRNA targets: cancer.
Running news: CEO Ugur Sahini New cell therapy data presented At the Society for Immunotherapy of Cancer conference in DC over the weekend.
“We have a blueprint now For infectious disease vaccines,” Sahin told a gathering of reporters about the impact of COVID vaccine development on the future of mRNA technology.
- This includes not only proving the mRNA technology, but also creating the necessary processes to develop and supply a product made from it, he said.
- Beyond COVID vaccines, his company is already conducting clinical trials on cancer immunotherapy candidates. But he believes the mRNA technology will be used for everything from vaccines for HIV, malaria and tuberculosis to applications in diseases of the heart and central nervous system.
- “This has opened a door for a new pharmaceutical class and we believe this innovation can be compared with the innovation of recombinant DNA technology almost 40 years ago,” Sahin said.